Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

Embecta (EMBC) stock gains as BTIG upgrades the stock citing an end to its patch pump program announced with its Q4 FY24 ...

On Tuesday, Embecta Corp (NASDAQ:EMBC) posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents ...

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

Q4 2024 Earnings Call Transcript November 26, 2024 Embecta Corp. misses on earnings expectations. Reported EPS is $ EPS, ...

Embecta Corporation (EMBC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Travis ...

Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.

BTIG upgraded Embecta (EMBC) to Buy from Neutral with a $26 price target Shares gained about 30% in Tuesday trading as investors rewarded ...

Algert Global LLC trimmed its holdings in shares of Embecta Corp. (NASDAQ:EMBC – Free Report) by 31.8% in the third quarter, ...

Q4 2024 Earnings Conference Call November 26, 2024 8:00 AM ETCompany ParticipantsPravesh Khandelwal - VP of IRDev Kurdikar ...

CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the company “did not intend to do a full market launch of this product.” ...

Embecta also said it expects to earn between $2.70 and $2.90 a share on an adjusted basis for all of 2025, easily surpassing the average analyst estimate of $2.27 per share. Revenue is anticipated at ...